Desialylation is a Mechanism of Fc-independent Platelet Clearance and a Therapeutic Target in Immune Thrombocytopenia
June Li,Dianne E. van der Wal,Guangheng Zhu,Miao Xu,Issaka Yougbare,Li Ma,Brian Vadasz,Naadiya Carrim,Renata Grozovsky,Min Ruan,Lingyan Zhu,Qingshu Zeng,Lili Tao,Zhi-min Zhai,Jun Peng,Ming Hou,Valery Leytin,John Freedman,Karin M. Hoffmeister,Heyu Ni
DOI: https://doi.org/10.1038/ncomms8737
IF: 16.6
2015-01-01
Nature Communications
Abstract:Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by autoantibodies against platelet GPIIbIIIa and/or the GPIb complex. Current theory suggests that antibody-mediated platelet destruction occurs in the spleen, via macrophages through Fc-FcγR interactions. However, we and others have demonstrated that anti-GPIbα (but not GPIIbIIIa)-mediated ITP is often refractory to therapies targeting FcγR pathways. Here, we generate mouse anti-mouse monoclonal antibodies (mAbs) that recognize GPIbα and GPIIbIIIa of different species. Utilizing these unique mAbs and human ITP plasma, we find that anti-GPIbα, but not anti-GPIIbIIIa antibodies, induces Fc-independent platelet activation, sialidase neuraminidase-1 translocation and desialylation. This leads to platelet clearance in the liver via hepatocyte Ashwell-Morell receptors, which is fundamentally different from the classical Fc-FcγR-dependent macrophage phagocytosis. Importantly, sialidase inhibitors ameliorate anti-GPIbα-mediated thrombocytopenia in mice. These findings shed light on Fc-independent cytopenias, designating desialylation as a potential diagnostic biomarker and therapeutic target in the treatment of refractory ITP.